Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...

Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Wolfe Research has recently raised Warner Bros Discovery Inc (WBD) stock to Peer Perform rating, as announced on November 11, 2024, according to Finviz. Earlier, on August 13, 2024, Bernstein had ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ:WBD) to Peer Perform from Underperform following its Q3 results last week, and assigned a fair value range of $ ...

Wolfe Research has upgraded Warner Bros. Discovery (WBD, Financials) to "peer perform" from "underperform," citing a balanced risk/reward outlook despite Warner Bros. Discoverys $40 billion in ...

agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will participate in the 2024 Wolfe Research Healthcare ...

Wolfe Research has upgraded Warner Bros. Discovery (WBD, Financials) to "peer perform" from "underperform," citing a balanced risk/reward outlook despite Warner Bros. Discoverys $40 billion in gross ...